Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07441278 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT07441278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07441278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Lead sponsor
NS Pharma, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 14, 2028
Enrollment
177 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with interstitial lung disease (ph-ild)